Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, Milu Labs to Develop Mass Spec Assays for Women's Health in China

NEW YORK – Thermo Fisher Scientific and Milu Labs said today that they plan to collaborate to develop clinical diagnostic technologies for women's health in China.

Under a memorandum of understanding, the companies plan to explore opportunities to use Thermo Fisher's liquid chromatography-mass spectrometry instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.

In particular, they plan to develop a clinical mass spectrometry-based proteomics assay that combines the NX Prenatal NeXosome platform and Thermo Fisher's mass spec technology to evaluate pregnancy biomarkers that correlate with adverse outcomes, such as preterm birth or preeclampsia.

Earlier this year, NX Prenatal inked a strategic collaboration with Milu Labs to commercialize its preterm birth risk test in Asia.

Milu Labs, a diagnostics company with offices in New York and Singapore, focuses on technologies to screen and detect major health conditions. The firm collaborates with academic institutions and companies to develop strategies for launching tests in China.